Direct Meds vs Medvi: How Two Compounded GLP-1 Programs Differ

Shoppers who type "Direct Meds vs Medvi" are usually weighing two programs that read almost the same on their landing pages. This PlexusDx Education Hub review lays out how each is assembled, where they actually diverge, and the one metabolic factor that sits outside both. Browse the full Peptides & GLP-1 library.

Full head-to-head: PlexusDx vs MEDVi →

Independent editorial note: PlexusDx holds no commercial relationship with Medvi, Direct Meds, or their parent companies. Nothing on this page is sponsored, and no affiliate links appear here.

Both brands are part of a crowded telehealth GLP-1 market that, as of April 2026, spans dozens of near-interchangeable offers. Rather than reskin a generic comparison, the sections below focus on the operational choices that separate one compounded program from another.

Direct Meds and Medvi at a glance

Medvi (operating as Medvi Wellness) and Direct Meds both run on the telehealth-plus-compounded-pharmacy model: a virtual clinical evaluation, a provider-issued prescription, and fulfillment through either brand-name FDA-approved dispensing or compounded semaglutide and tirzepatide routed to a licensed compounding pharmacy. Program specifics, medication menus, and prices are published on each brand's own site, so check Medvi's website and Direct Meds's current listing before drawing conclusions.

The 503A compounding pathway both lean on

When either platform dispenses compounded semaglutide or tirzepatide, that product comes from a 503A compounding pharmacy rather than a branded manufacturer. Compounded formulations are prepared for an individual patient under a prescription; they are not the same commercial products sold under brand names. Understanding which pathway a given order uses matters more than the marketing label attached to it.

Where a genuine difference shows up

Because the pharmacology is shared, the meaningful contrasts are operational: whether a physician or an NP/PA signs off, how tightly follow-up is scheduled, whether billing is month-to-month or a longer subscription, and whether the default fill is branded or compounded. Those choices shape the day-to-day experience far more than any slogan about results.

Reading the price tag on either program

Cash-pay totals across telehealth GLP-1 programs varied widely as of April 2026, with monthly figures commonly landing somewhere between roughly $200 and $700 or more once program fees, medication, and compounding are combined. Neither Direct Meds nor Medvi publishes a single flat number that fits every patient, so verify the current cost directly on each brand's pricing page rather than trusting a screenshot.

The evidence belongs to the molecule, not the brand

The clinical record here attaches to the compound class rather than any platform. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide were studied in trial programs such as STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Effect sizes differ by compound, dose, and population, and the mechanism travels with the molecule regardless of who prescribes it.

The genetic layer sitting upstream of both

What neither Direct Meds nor Medvi maps is the inherited metabolic terrain a GLP-1 compound acts on. A variant in GLP1R, the gene that codes for the GLP-1 receptor itself, describes the target every one of these drugs binds; FTO shapes fat-mass and appetite biology alongside it. These markers are pathway-level context, not response predictions. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, and PlexusDx dispenses its own protocols through the Weight Management Protocols collection, including Semaglutide Injection and Tirzepatide Injection. Knowing that profile turns a prescription decision into an informed conversation with your clinician.

Not affiliated: PlexusDx is independent of both Medvi and Direct Meds and has no commercial relationship with the companies reviewed above.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This comparison is educational. PlexusDx is not affiliated with Medvi or Direct Meds and sells semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols for semaglutide and tirzepatide, or begin upstream with the Precision Peptide Genetic Test to map your GLP-1 pathway before you commit.

Frequently Asked Questions

Is Direct Meds or Medvi the better GLP-1 choice?

Neither is objectively superior. Both sit in the compounded telehealth GLP-1 category with comparable structures, so fit comes down to provider model, follow-up cadence, billing terms, and which dispensing pathway a patient prefers. Review each brand's own disclosures rather than relying on a ranking.

Do Direct Meds and Medvi use compounded or brand-name medication?

Both can route prescriptions to a 503A compounding pharmacy for compounded semaglutide or tirzepatide, and both may dispense FDA-approved brand products depending on the plan. The exact fill for a given order is spelled out on each brand's site, so confirm the pathway before ordering rather than assuming.

How does the Precision Peptide Genetic Test fit a comparison like this?

It sits upstream of either program. The test does not predict how you will respond to a Direct Meds or Medvi prescription; it reads pathway-level variants such as FTO that describe your baseline GLP-1 biology, context that applies no matter which telehealth service ultimately writes the script.

How does PlexusDx differ from these two platforms?

PlexusDx pairs its own semaglutide and tirzepatide protocols with genetic pathway mapping through the Precision Peptide Genetic Test. That upstream layer, covering variants like FTO, is the piece most compounded telehealth programs, Direct Meds and Medvi included, leave out of the prescribing conversation.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education